Planta Med 2004; 70(5): 397-400
DOI: 10.1055/s-2004-818965
Original Paper
Pharmacology
© Georg Thieme Verlag KG Stuttgart · New York

Silibinin Down-Regulates Prostate Epithelium-Derived Ets Transcription Factor in LNCaP Prostate Cancer Cells

Paul Thelen1 , Hubertus Jarry2 , Rolf-Hermann Ringert1 , Wolfgang Wuttke2
  • 1Department of Urology, Georg-August-University, Göttingen, Germany
  • 2Department of Clinical and Experimental Endocrinology, Georg-August-University, Göttingen, Germany
This study was supported by the European Union: (E)UROESTROGEN(E)S contract QLK6-CT-200-00 656
Further Information

Publication History

Received: September 22, 2003

Accepted: January 30, 2004

Publication Date:
04 May 2004 (online)

Abstract

The androgen-sensitive human prostate cancer cell line LNCaP expresses the estrogen receptor β and androgen receptor and can be stimulated by androgens to secrete prostate-specific antigen (PSA). In this study we demonstrate the cancer protective potential of silibinin, a flavolignan derived from the fruits of Silybum marianum, which down-regulates the co-activator of the androgen receptor, the prostate epithelium-derived Ets transcription factor (PDEF) and consequently the secretion of PSA. LNCaP cells were treated with various concentrations of silibinin in the presence or in the absence of 5α-dihydrotestosterone (DHT). We used real-time RT-PCR to quantify mRNA expression of PDEF and PSA with gene-specific dual-labelled fluorescence probes. PSA secretion from LNCaP cells in conditioned media was measured with the Elecsys® System 2010. Silibinin down-regulated PSA mRNA expression and PSA secretion in conditioned medium under basal and DHT (10 - 8 M) stimulated conditions, which was paralleled by PDEF down-regulation. DHT alone stimulated PDEF and PSA gene expression and PSA secretion. The down-regulation of basal as well as DHT stimulated PDEF and PSA by silibinin demonstrates the antiproliferative potential of this agent. These effects underline the possible therapeutic use of silibinin in the management of prostate cancer.

Abbreviations

Ets:E twenty-six transcription factor

PDEF:prostate epithelium-derived Ets factor

DHT:5α-dihydrotestosterone

PSA:prostate-specific antigen

IGFBP-3:insulin-like growth factor-binding protein 3

ER:estrogen receptor

cRNA:complementary RNA

References

  • 1 Sutkowski D M, Goode R L, Baniel J, Teater C, Cohen P, McNulty A M. et al . Growth regulation of prostatic stromal cells by prostate-specific antigen.  J Natl Cancer Inst.. 1999;  91 1663-9
  • 2 Lau K M, LaSpina M, Long J, Ho S M. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation.  Cancer Res.. 2000;  60 3175-82
  • 3 Adams J Y, Leav I, Lau K M, Ho S M, Pflueger S M. Expression of estrogen receptor beta in the fetal, neonatal, and prepubertal human prostate.  Prostate.. 2002;  52 69-81
  • 4 Seidlová-Wuttke D, Becker T, Christoffel V, Jarry H Wuttke W. Silymarin is a selective estrogen receptor β (ERβ) agonist and has estrogenic effects in the metaphysis of the femur but no or antiestrogenic effects in the uterus of ovariectomized (ovx) rats.  J Steroid Biochem Mol Biol. 2003;  86 179-88
  • 5 Bhatia N, Agarwal R. Detrimental effect of cancer preventive phytochemicals silymarin, genistein and epigallocatechin 3-gallate on epigenetic events in human prostate carcinoma DU145 cells.  Prostate. 2001;  46 98-107
  • 6 Zi X, Zhang J, Agarwal R, Pollak M. Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells.  Cancer Res. 2000;  60 5617-20
  • 7 Zi X, Agarwal R. Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention.  Proc Natl Acad Sci USA. 1999;  96 7490-5
  • 8 Zhu W, Zhang J S, Young C Y. Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP.  Carcinogenesis. 2001;  22 1399-403
  • 9 Oettgen P, Finger E, Sun Z, Akbarali Y, Thamrongsak U, Boltax J. et al . PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression.  J Biol Chem. 2000;  275 1216-25
  • 10 Ghadersohi A, Sood A K. Prostate epithelium-derived Ets transcription factor mRNA is overexpressed in human breast tumors and is a candidate breast tumor marker and a breast tumor antigen. Clin.  Cancer Res. 2001;  7 2731-8
  • 11 Finke J, Fritzen R, Ternes P, Lange W, Dolken G. An improved strategy and a useful housekeeping gene for RNA analysis from formalin-fixed, paraffin-embedded tissues by PCR.  Biotechniques. 1993;  14 448-53
  • 12 Grzmil M, Thelen P, Hemmerlein B, Schweyer S, Voigt S, Mury D. et al . Bax inhibitor-1 is overexpressed in prostate cancer and its specific down-regulation by RNA interference leads to cell death in human prostate carcinoma cells.  Am J Pathol. 2003;  163 543-52
  • 13 Tyagi A, Bhatia N, Condon M S, Bosland M C, Agarwal C, Agarwal R. Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells.  Prostate. 2002;  53 211-17
  • 14 Chen H, Nandi A K, Li X, Bieberich C J. NKX-3.1 interacts with prostate-derived Ets factor and regulates the activity of the PSA promoter.  Cancer Res. 2002;  62 338-40
  • 15 Abate-Shen C. Deregulated homeobox gene expression in cancer: cause or consequence? Nat. Rev.  Cancer. 2002;  2 777-85

Dr. Paul Thelen

Abt. Urologie

Georg-August-Universität

Robert Koch-Str. 40

37075 Göttingen

Germany

Phone: +49-551-398-651

Fax: +49-551-396-165

Email: pthelen@gwdg.de

    >